

Leqvio - Dosing and administration - HCP

[Prescribing information](#)

Image



Image



**LEQVIO®▼ (inclisiran) may help your patients reach LDL-C targets with 2 maintenance doses a year in combination with a maximally tolerated statin<sup>1</sup>**

**After an initial dose, LEQVIO® is administered again at 3 months, followed by every 6 months<sup>1</sup>**

LEQVIO® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:<sup>1</sup>

- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or

- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

**For full safety information, please refer to the LEQVIO® Summary of Product Characteristics.**

---

## **LEQVIO® dosing and administration**

**LEQVIO® is the first and only siRNA LDL-C-lowering therapy,<sup>1-3</sup> with the convenience of**

Image



- **HCP-administered**
- **Subcutaneous injection**
- **No refrigeration required**
- **Fixed dose**
- **No additional monitoring blood tests mandated<sup>†</sup>**
- **Does not add to pill burden**

\*After an initial dose, LEQVIO® is administered again at 3 months, followed by every 6 months.<sup>1</sup>

<sup>†</sup>Beyond what is already clinically indicated for your patient.

**No data are available in patients with severe hepatic impairment (Child-Pugh class C). LEQVIO® should be used with caution in patients with severe hepatic impairment.**

**There is limited experience with LEQVIO® in patients with severe renal impairment. LEQVIO® should be used with caution in these patients.**

**The effect of haemodialysis on LEQVIO® pharmacokinetics has not been studied. Considering that LEQVIO® is eliminated renally, haemodialysis should not be performed for at least 72 hours after LEQVIO® dosing.**

---

Watch the short video below to learn more about LEQVIO® administration, including a step-by-step guide for injection.

# GUIDE TO USING **LEQVIO**<sup>®</sup> inclisiran

LEQVIO<sup>®</sup> (inclisiran) is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet.<sup>1</sup>

- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated

LDL-C – low-density lipoprotein cholesterol.

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard).  
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

LEQVIO<sup>®</sup> is intended for administration by a healthcare professional.

For detailed instructions for use, please see the package leaflet.

Prescribing information can be found on the web page on which this video is shown.

Promotional material produced and funded by Novartis for UK healthcare professionals only.

Reference: 1. LEQVIO<sup>®</sup> Summary of Product Characteristics.


UK | December 2024 | FA-11303613

## VIDEO

### Subcutaneous administration of LEQVIO<sup>®</sup>:<sup>1</sup>

The recommended dose of LEQVIO<sup>®</sup> is 284 mg, administered via a single pre-filled syringe: initially, again at 3 months, and thereafter every 6 months.

Image



For full information on LEQVIO<sup>®</sup> dosing and administration, please refer to the SmPC.

### Additional dosing and administration information<sup>1</sup>

Image



No dose adjustments are required for patients with mild or moderate hepatic impairment, mild, moderate or severe renal impairment or end-stage renal disease, or elderly patients (age  $\geq 65$  years).

Image



Check the LEQVIO® solution for injection visually before administration – it should be clear, colourless to pale yellow and essentially free of particles. If the solution contains visible particulate matter, the solution should not be used. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Image



Areas to avoid: active skin disease or injury (e.g. sunburns, skin rashes, inflammation, skin infections).

Image



If a planned dose is missed by less than 3 months, LEQVIO® should be administered and dosing continued according to the patient's original schedule. If a planned dose is missed by more than 3 months, a new dosing schedule should be started – LEQVIO® should be administered initially, again at 3 months, followed by every 6 months.

Image



LEQVIO® is administered by a healthcare professional into the abdomen, upper arm or thigh.

Image





Abdomen



Upper arm



Thigh

**For further information, please refer to the SmPC.**

**With over 12,000 patient-years exposure and >20,000 injections, the safety profile of LEQVIO® remains consistent, with no new safety signals identified in the ORION-8 open-label extension study<sup>†4</sup>**

---

Image



**With straightforward twice-yearly maintenance dosing, LEQVIO® can be administered during existing patient appointments<sup>1</sup>**

After an initial dose, LEQVIO® is administered again at 3 months, followed by every 6 months.<sup>1</sup>

**Explore LEQVIO® eligibility criteria**

[Primary care](#)

**Explore LEQVIO® eligibility criteria**

[Secondary care](#)

---

<sup>†</sup>A pooled cohort of 3274 patients treated with LEQVIO® with an assumed dosing frequency of two injections per year and an average treatment duration of 3.7 years.<sup>4</sup>

HCP, healthcare professional; LDL-C, low-density lipoprotein cholesterol; siRNA, small interfering ribonucleic acid; SmPC, summary of product characteristics.

---

## References

1. LEQVIO® Summary of Product Characteristics.
2. Stoekenbroek RM, et al. *Future Cardiol* 2018;14(6):433-442.
3. Klinovski M, et al. Inclisiran: a small interfering RNA molecule for treating hypercholesterolemia. Ottawa: CADTH; 2019. *CADTH Issues in Emerging Health Technologies*; Issue 180.
4. Wright RS, et al. Oral presentation. ORION-8: Long-term efficacy and safety of twice-yearly inclisiran in high cardiovascular risk patients. ESC Congress 2023. Amsterdam, The Netherlands, 25-28 August 2023.

LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG. Licensed from Alnylam Pharmaceuticals, Inc.

UK | January 2025 | FA-11205606

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report), or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

---

**Source URL:** <https://www.pro.novartis.com/uk-en/medicines/cardio-metabolic/leqvio/dosing>